Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2026
Reporting Period: Single event date (August 5, 2026)
Business Context: The Company is a Delaware corporation with principal executive offices in New York, NY. This filing serves as a Regulation FD disclosure regarding a specific operational milestone.
Key Financial Metrics
This Form 8-K is a current report regarding a non-financial event and does not contain audited or unaudited financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Operational Milestone: On August 5, 2026, the Company announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System. This represents a material development in the Company's product pipeline rather than a financial change versus a prior period.
Guidance, Outlook, and Risks
- Management Commentary: The filing references a press release (Exhibit 99.1) detailing the study completion. The disclosure is qualified in its entirety by the full text of that press release.
- Forward-Looking Statements: The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, nor incorporated by reference unless specifically identified.
- Risks and Contingencies: No specific financial risks or contingencies are detailed within the body of this 8-K text.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to understand the specific results and implications of the completed Usability Study.
- Verify the regulatory status and next steps for the Intelligent Fingerprinting Drug Screening System following the study completion.
- Check subsequent filings for any financial impact or updated guidance resulting from this operational milestone.